Genmab — Juni 2018
-
-
-
-
GB. Ved du om det er et gennemgående tema mht. både patientudvælgelse og fremlæggelse af resultater i forhold til Bluebird?
-
Nej
-
Ok. Synes blot at jeg herinde har set noget angår de
-
angående patientudvælgelsen før.
-
Hvad jeg får ud af at læse på Twitter, er at bb2121 er rigtig godt når alt andet inclusive dara er prøvet. Altså mindst 5-6 linie behandling. Patienterne har her ikke andre muligheder end CAR-T.
-
Ok. Tak.
-
Men BLUE og CELGENE vil givetvis gøre alt for at få det frem til mindst 3. linie. Ellers bliver deres investeringer aldrig rentable. Og så kan det jo tage noget fra dara
-
Men generelt tror jeg ikke vi behøver frygte et CAR-T hype som vi sà efter ASH
-
Yes EL. Thank you. It was to assess whether it was an even playing field concerning the outcome of the trials. If the selection process is very biased it is certainly something to consider.
-
@GB. Ja der er ikke noget at sige til at de vil frem i verden, men det skal jo være pga.et godt produkt, og ikke pga. hype.
-
Yes. It is very little and very late - and furthermore based
-
Enig. Men de vil gøre alt for at forsvare deres investering.
-
on a very futuristiske assessment.
-
Det forstår jeg godt, men data er med dara indtil videre:)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind